Literature DB >> 29391600

PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.

Yanlin Yu1, Meng Dai2, Andrew Lu3, Ellen Yu3, Glenn Merlino3.   

Abstract

PI3K/AKT pathway activation is thought to be a driving force in metastatic melanomas. Members of the pleckstrin homology (PH) domain leucine-rich repeat protein Ser/Thr specific phosphatase family (PHLPP1 and PHLPP2) can regulate AKT activation. By dephosphorylating specific serine residues in the hydrophobic motif, PHLPP1 and PHLPP2 restrain AKT signalings, thereby regulating cell proliferation and survival. We here show that PHLPP1 expression was significantly downregulated or lost and correlated with metastatic potential in melanoma. Forcing expression of either PHLPP1 or PHLPP2 in melanoma cells inhibited cell proliferation, migration, and colony formation in soft agar; but PHLPP1 had the most profound inhibitory effect on metastasis. Moreover, expression of PH mutant forms of PHLPP1 continued to inhibit metastasis, whereas a phosphatase-dead C-terminal mutant did not. The introduction of activated PHLPP1-specific targets AKT2 or AKT3 also promoted melanoma metastasis, while the non-PHLPP1 target AKT1 did not. AKT2 and AKT3 could even rescue the PHLPP1-mediated inhibition of metastasis. An AKT inhibitor blocked the activity of AKT2 and inhibited AKT2-mediated tumor growth and metastasis in a preclinical mouse model. Our data demonstrate that PHLPP1 functions as a metastasis suppressor through its phosphatase activity, and suggest that PHLPP1 represents a novel diagnostic and therapeutic marker for metastatic melanoma.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29391600      PMCID: PMC6450546          DOI: 10.1038/s41388-017-0061-7

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  50 in total

Review 1.  Oncogenic kinase signalling.

Authors:  P Blume-Jensen; T Hunter
Journal:  Nature       Date:  2001-05-17       Impact factor: 49.962

2.  The phosphatase PHLPP1 regulates Akt2, promotes pancreatic cancer cell death, and inhibits tumor formation.

Authors:  Claudia Nitsche; Mouad Edderkaoui; Ryan M Moore; Guido Eibl; Noriyuki Kasahara; Janet Treger; Paul J Grippo; Julia Mayerle; Markus M Lerch; Anna S Gukovskaya
Journal:  Gastroenterology       Date:  2011-10-29       Impact factor: 22.682

3.  Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma.

Authors:  Victoria Marsh Durban; Marian M Deuker; Marcus W Bosenberg; Wayne Phillips; Martin McMahon
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

Review 4.  The functions and regulation of the PTEN tumour suppressor.

Authors:  Min Sup Song; Leonardo Salmena; Pier Paolo Pandolfi
Journal:  Nat Rev Mol Cell Biol       Date:  2012-04-04       Impact factor: 94.444

5.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth.

Authors:  Tianyan Gao; Frank Furnari; Alexandra C Newton
Journal:  Mol Cell       Date:  2005-04-01       Impact factor: 17.970

6.  Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators.

Authors:  Yanlin Yu; Javed Khan; Chand Khanna; Lee Helman; Paul S Meltzer; Glenn Merlino
Journal:  Nat Med       Date:  2004-01-04       Impact factor: 53.440

7.  Loss expression of PHLPP1 correlates with lymph node metastasis and exhibits a poor prognosis in patients with gastric cancer.

Authors:  Zhixiong Wang; Haihua Shu; Zhao Wang; Guanghua Li; Ji Cui; Hui Wu; Shirong Cai; Weiling He; Yulong He; Wenhua Zhan
Journal:  J Surg Oncol       Date:  2013-08-26       Impact factor: 3.454

8.  LFIRE-1/HFREP-1, a liver-specific gene, is frequently downregulated and has growth suppressor activity in hepatocellular carcinoma.

Authors:  Jun Yan; Yanlin Yu; Nan Wang; Yunchao Chang; Hao Ying; Weizhong Liu; Jin He; Shenqing Li; Wanli Jiang; Yuli Li; Huimin Liu; Hongyang Wang; Yonghua Xu
Journal:  Oncogene       Date:  2004-03-11       Impact factor: 9.867

9.  Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy.

Authors:  Martine J Jager; Robert M Verdijk; Jinfeng Cao; Renier C Heijkants; Aart G Jochemsen; Mehmet Dogrusöz; Mark J de Lange; Pieter A van der Velden; Sjoerd H van der Burg
Journal:  Oncotarget       Date:  2016-07-22

10.  Akt2 regulates metastatic potential in neuroblastoma.

Authors:  Jingbo Qiao; Sora Lee; Pritha Paul; Lan Qiao; Chase J Taylor; Cameron Schlegel; Nadja C Colon; Dai H Chung
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

View more
  11 in total

1.  TIS21/BTG2 inhibits breast cancer growth and progression by differential regulation of mTORc1 and mTORc2-AKT1-NFAT1-PHLPP2 signaling axis.

Authors:  Santhoshkumar Sundaramoorthy; Preethi Devanand; Min Sook Ryu; Kye Yong Song; Dong Young Noh; In Kyoung Lim
Journal:  J Cancer Res Clin Oncol       Date:  2018-05-28       Impact factor: 4.553

2.  miR-141 Promotes Colon Cancer Cell Proliferation by Targeted PHLPP2 Expression Inhibitionn.

Authors:  Fazhuang Fang; Ling Cheng; Xiaotang Wu; Minfeng Ye; Huizhong Zhang
Journal:  Cancer Manag Res       Date:  2020-11-06       Impact factor: 3.989

3.  PHLPP2 as a novel metastatic and prognostic biomarker in non-small cell lung cancer patients.

Authors:  Hongmei Wang; Ruixue Gu; Fanglin Tian; Yuechao Liu; Weina Fan; Guiqin Xue; Li Cai; Ying Xing
Journal:  Thorac Cancer       Date:  2019-09-30       Impact factor: 3.500

Review 4.  The Multifaceted Role of CMA in Glioma: Enemy or Ally?

Authors:  Alessia Lo Dico; Cristina Martelli; Cecilia Diceglie; Luisa Ottobrini
Journal:  Int J Mol Sci       Date:  2021-02-23       Impact factor: 5.923

5.  PHLPP1 Overexpression was Associated With a Good Prognosis With Decreased AKT Activity in Gastric Cancer.

Authors:  Sun Yi Park; Sang-Ho Jeong; Eun-Jung Jung; Young-Tae Ju; Chi-Young Jeong; Ju-Yeon Kim; Taejin Park; Jiho Park; Tae-Han Kim; Miyeong Park; Jung Wook Yang; Young-Joon Lee
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 6.  Genomic and Transcriptomic Underpinnings of Melanoma Genesis, Progression, and Metastasis.

Authors:  Olga S Cherepakhin; Zsolt B Argenyi; Ata S Moshiri
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

7.  AKT1 Is Required for a Complete Palbociclib-Induced Senescence Phenotype in BRAF-V600E-Driven Human Melanoma.

Authors:  Abraham L Bayer; Jodie Pietruska; Jaymes Farrell; Siobhan McRee; Pilar Alcaide; Philip W Hinds
Journal:  Cancers (Basel)       Date:  2022-01-23       Impact factor: 6.639

8.  PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN.

Authors:  Yifei Qin; Qiang Zuo; Lei Huang; Liping Huang; Glenn Merlino; Yanlin Yu
Journal:  NPJ Precis Oncol       Date:  2021-07-19

9.  PHLPP1 is a metastasis suppressor in melanoma.

Authors:  Meng Dai; Yanlin Yu
Journal:  Aging (Albany NY)       Date:  2018-09-05       Impact factor: 5.682

10.  Silencing of TRIM11 suppresses the tumorigenicity of chordoma cells through improving the activity of PHLPP1/AKT.

Authors:  Bin Wang; Gang Wang; Qingfeng Wang; Ziqiang Zhu; Yunqing Wang; Kangwu Chen; Huilin Yang
Journal:  Cancer Cell Int       Date:  2019-11-08       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.